Crucell Awarded Contracts of Over $230 Million for Quinvaxem and Hepavax-Gene Vaccines

04-Dec-2006

Flexible all-rounder: The multi-mode microplate reader with best-in-class sensitivity

Shaken bioreactors with in-situ gas analysis

Crucell N.V. announced that it has been awarded contracts totaling over US $230 million for its Quinvaxem(TM) and Hepavax-Gene® paediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those three years. Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.

Quinvaxem(TM), a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell's laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b.

The Hepavax-Gene®, recombinant hepatitis B vaccine, is one of the WHO's pre-qualified vaccines for active immunization against the hepatitis B virus.

https://www.bionity.com/en/news/59854/crucell-awarded-contracts-of-over-230-million-for-quinvaxem-and-hepavax-gene-vaccines.html